Skip to content

Diagnostic Value of Ultralow-dose Computed Tomography for the Detection of Pulmonary Nodules and Lung Parenchym Alterations Compared to Standard-dose CT

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02468609
Acronym
RADFL
Enrollment
500
Registered
2015-06-11
Start date
2015-01-31
Completion date
2016-12-31
Last updated
2016-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Pulmonary Nodules, Pulmonary Emphysema

Brief summary

To investigate the diagnostic value of ultralow-dose computed tomography in the detection of pulmonary nodules and lung parenchym alterations (e.g. emphysema) compared to standard-dose-CT.

Interventions

RADIATIONUltralow-Dose-CT

Patients undergoing thoracic normal dose-CT with undergo an additional Ultralow-Dose-CT

Sponsors

Cantonal Hospital of St. Gallen
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* planned normal dose-CT by clinical indication at our institution * obtained informed consent

Exclusion criteria

* planned lowdose-CT by clinical indication at institution * no informed consent obtained * age \< 18 years * pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Number of pulmonary Nodules detected in the Ultralow-Dose thoracic CTParticipants CT-scan will be read out on an average date of 6 weeks after the scanDifference in nodule detectability in Ultralow-Dose-CT compared to Standard-Dose-CT measured using McNemar test

Secondary

MeasureTime frame
Patients BMI (Body mass index)Measures assessed at time of read-out on an average date of 6 weeks after the scan
Patients Nodule size (mm)Measures assessed at time of read-out on an average date of 6 weeks after the scan

Countries

Switzerland

Contacts

Primary ContactMichael A Messerli, MD
Michael.Messerli@kssg.ch0041 71 494 66 66

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026